Johanna Mercier, Chief Commercial and Corporate Affairs Officer at Gilead Sciences, Inc. (NASDAQ:GILD), filed a Form 4 on September 16, 2026, disclosing the sale of 3,000 shares of common stock on September 15, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Johanna Mercier, Chief Commercial and Corporate Affairs Officer at Gilead Sciences, Inc.
  • Shares sold: 3,000 total shares of common stock disposed of across three transactions on September 15, 2026.
  • Sale prices: 1,600 shares at a weighted average of $143.6917, 800 shares at a weighted average of $144.4569, and 600 shares at $145.29.
  • Remaining ownership: 116,684 shares of common stock held directly following the reported transactions.
  • Trading plan: All sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
  • Filing signed: Amy Kim, by Power of Attorney for Johanna Mercier, on September 16, 2026.

Mercier's Three-Tranche Share Sale Under Pre-Set Trading Plan

According to the filing, Johanna Mercier disposed of Gilead Sciences common stock in three separate transactions, all dated September 15, 2026. The first transaction involved 1,600 shares sold at a weighted average price of $143.6917, with the filing noting that individual sale prices ranged from $143.16 to $144.15. The second transaction covered 800 shares at a weighted average of $144.4569, with prices ranging from $144.26 to $144.775. The third transaction was 600 shares sold at $145.29, with no price range noted for that tranche.

The filing states that all three transactions were "made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025." Rule 10b5-1 plans allow corporate insiders to establish pre-scheduled trading arrangements at a time when they are not in possession of material nonpublic information. The filing notes that full details on shares sold at each individual price are available upon request to the SEC, the issuer, or its shareowners.

Following the three disposals, Mercier's direct beneficial ownership of Gilead Sciences common stock stood at 116,684 shares, according to the filing. No derivative securities transactions were reported in Table II. The form was signed by Amy Kim acting under a Power of Attorney for Johanna Mercier and was filed on September 16, 2026.

What Was Disclosed

The filing disclosed three sales of Gilead Sciences common stock totaling 3,000 shares by Chief Commercial and Corporate Affairs Officer Johanna Mercier on September 15, 2026, all executed under a pre-established Rule 10b5-1 plan, leaving her with 116,684 directly held shares.